肿瘤细胞治疗研究
英文原题：Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).
严重急性呼吸综合征冠状病毒 2（SARS CoV 2）具有高度传染性和致病性。
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）具有高度传染性和致病性。对于SARS-CoV-2导致的2019冠状病毒病（COVID-19）重症患者，合并恶性肿瘤者由于肿瘤消耗、营养不良和抗肿瘤治疗导致免疫功能受损，更容易感染并发生重症。癌症与COVID-19患者重症和死亡风险密切相关。SARS-CoV-2可能促进肿瘤进展，并刺激肿瘤细胞代谢转换，使其启动效率更高的代谢模式（如糖酵解），以支持SARS-CoV-2大量复制。然而，研究显示SARS-CoV-2感染可延缓自然杀伤（NK）细胞淋巴瘤和霍奇金淋巴瘤患者的肿瘤进展；SARS-CoV-2诱导的抗肿瘤免疫应答可能对淋巴瘤患者发挥潜在溶瘤作用。本文简要总结SARS-CoV-2潜在致癌性和溶瘤特征，以及COVID-19大流行期间保护癌症患者的策略。
Severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) is highly infectious and pathogenic. Among patients with severe SARS CoV 2 caused by corona virus disease 2019 (COVID 19), those complicated with malignant tumor are vulnerable to COVID 19 due to compromised immune function caused by tumor depletion, malnutrition and anti tumor treatment. Cancer is closely related to the risk of severe illness and mortality in patients with COVID 19. SARS CoV 2 could promote tumor progression and stimulate metabolism switching in tumor cells to initiate tumor metabolic modes with higher productivity efficiency, such as glycolysis, for facilitating the massive replication of SARS CoV 2. However, it has been shown that infection with SARS CoV 2 leads to a delay in tumor progression of patients with natural killer cell (NK cell) lymphoma and Hodgkin's lymphoma, while SARS CoV 2 elicited anti tumor immune response may exert a potential oncolytic role in lymphoma patients. The present review briefly summarized potential carcinogenicity and oncolytic characteristics of SARS CoV 2 as well as strategies to protect patients with cancer during the COVID 19 pandemic.
MEMBER ACCOUNT
登录成功会直接打开下一页。
